Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating eloralintide, a drug given by injection, for its effects on body weight reduction in adults who are overweight or have obesity along with type 2 diabetes. The study aims to compare eloralintide with a placebo to assess its safety and effectiveness. Participation will last approximately 75 weeks, providing a thorough evaluation period. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all administered by subcutaneous injection once weekly. This phase 3, double-blind study ensures that neither participants nor researchers know which treatment is given, maintaining unbiased results. The treatment period lasts up to 64 weeks, with ongoing monitoring throughout. During the study, participants will have regular visits to assess changes in body weight, body fat, waist size, blood sugar control HbA1c, blood pressure, and other health markers. Questionnaires about physical function, eating behavior, and quality of life will also be collected. Safety will be monitored continuously, and the main measurement is the percent change in body weight at week 64 compared to the start. Participants involvement will last about 75 weeks in total.
Actively Recruiting
Researchers are evaluating the safety and effects of berobenatide PF-08653944 in adults with obesity disease, a condition characterized by excess body fat that can harm health and increase the risk of other medical problems. Some participants may also have type 2 diabetes, where the body does not use insulin properly, leading to high blood sugar levels. This Phase 3 clinical trial is being conducted in Japan to better understand how berobenatide works for people with these conditions. Participants will be randomly assigned to receive either berobenatide or a placebo. Both treatments are given as injections under the skin of the abdomen once a week. The study compares the effects of berobenatide to placebo in helping people lose weight and examines its safety. About 180 adults will participate, and the study includes up to 15 in-person visits and 2 phone visits over approximately 22 months. During the study, participants will have their body weight and waist circumference measured, along with blood pressure and blood tests to check glucose, insulin, cholesterol, and inflammation markers. Questionnaires about quality of life related to weight will also be completed. Researchers will monitor for any side effects or adverse events. The main outcome is the percent change in body weight from the start to week 72, with other health measures also tracked throughout the trial.